

HR 7472

Discounted Drugs for Clinical Trials Act

Congress: 117 (2021–2023, Ended)

Chamber: House

Policy Area: Health

Introduced: Apr 7, 2022

Current Status: Referred to the Subcommittee on Health.

Latest Action: Referred to the Subcommittee on Health. (Apr 8, 2022)

Official Text: <https://www.congress.gov/bill/117th-congress/house-bill/7472>

Sponsor

Name: Rep. Maloney, Carolyn B. [D-NY-12]

Party: Democratic • **State:** NY • **Chamber:** House

Cosponsors (5 total)

| Cosponsor | Party / State | Role | Date Joined |
|-------------------------------------|---------------|------|-------------|
| Rep. DeSaulnier, Mark [D-CA-11] | D · CA | | Apr 7, 2022 |
| Rep. Porter, Katie [D-CA-45] | D · CA | | Apr 7, 2022 |
| Rep. Raskin, Jamie [D-MD-8] | D · MD | | Apr 7, 2022 |
| Rep. Schakowsky, Janice D. [D-IL-9] | D · IL | | Apr 7, 2022 |
| Rep. Welch, Peter [D-VT-At Large] | D · VT | | Apr 7, 2022 |

Committee Activity

| Committee | Chamber | Activity | Date |
|-------------------------------|---------|-------------|-------------|
| Energy and Commerce Committee | House | Referred to | Apr 8, 2022 |

Subjects & Policy Tags

Policy Area:

Health

Related Bills

| Bill | Relationship | Last Action |
|------------|--------------|--|
| 117 S 4026 | Related bill | Apr 7, 2022: Read twice and referred to the Committee on Health, Education, Labor, and Pensions. |
| 117 S 4053 | Related bill | Apr 7, 2022: Read twice and referred to the Committee on Health, Education, Labor, and Pensions. |

Discounted Drugs for Clinical Trials Act

This bill allows researchers to obtain certain high-cost drugs and biologics at discounted prices from manufacturers. Researchers must apply to the Food and Drug Administration for approval; manufacturers must sell the approved quantity of drugs to researchers at the discounted price and are subject to civil actions from researchers for noncompliance.

Actions Timeline

- **Apr 8, 2022:** Referred to the Subcommittee on Health.
- **Apr 7, 2022:** Introduced in House
- **Apr 7, 2022:** Referred to the House Committee on Energy and Commerce.